{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-183073","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2025-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.949925+00:00","generated_at":"2026-05-17T11:23:30.766068+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rein Therapeutics gets UK MHRA nod for Phase 2 IPF trial of LTI-03","bullets":["UK MHRA authorized Phase 2 'RENEW' trial of LTI-03 for idiopathic pulmonary fibrosis (IPF).","Trial will enroll up to 120 patients globally; two dose groups vs placebo over 24 weeks.","Primary endpoint: safety/tolerability; secondary: lung function and imaging-based fibrosis measures.","Patient recruitment in UK to begin soon; initial data expected in 2026.","LTI-03 is first-in-class, designed to target fibrosis and protect lung regeneration; IPF median survival is 3-5 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-183073","json":"https://secwatch.observer/filing/0001193125-25-183073.json","markdown":"https://secwatch.observer/filing/0001193125-25-183073.md","text":"https://secwatch.observer/filing/0001193125-25-183073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525183073/0001193125-25-183073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525183073/d938122d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:23:30.766068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}